Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology industries, surprising investors with a $100 million revenue shortfall that led ...
Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Icon (ICLR – Research Report) today and set a price target of ...
J.P. Morgan analyst Casey Woodring maintained a Buy rating on Icon (ICLR – Research Report) on February 1 and set a price target of $265.00.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback